Aflatoxin B1 metabolism (WP699)

Homo sapiens

'''Aflatoxins''' are naturally occurring [[wikipedia:mycotoxin|mycotoxin]]s that are produced by many species of ''[[wikipedia:Aspergillus|Aspergillus]]'', a [[wikipedia:fungus|fungus]], most notably ''[[wikipedia:Aspergillus flavus|Aspergillus flavus]]'' and ''[[wikipedia:Aspergillus parasiticus|Aspergillus parasiticus]]''. After entering the body, aflatoxins are metabolized by the liver to a reactive intermediate, aflatoxin M1, an [[wikipedia:epoxide|epoxide]]. Aflatoxin B1 is considered the most toxic and is produced by both Aspergillus flavus and Aspergillus parasiticus. Source: [[wikipedia:Aflatoxin|Wikipedia]] Proteins on this pathway have targeted assays available via the [ CPTAC Assay Portal]


Pieter Giesbertz , Alex Pico , Thomas Kelder , Martijn Van Iersel , Christine Chichester , Martina Summer-Kutmon , Denise Slenter , Egon Willighagen , and Kristina Hanspers


last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.


Homo sapiens



Disease Ontology


Pathway Ontology

xenobiotic metabolic pathway cellular detoxification pathway aflatoxin metabolic pathway


Label Type Compact URI Comment
Aflatoxin B1 exo-8,9-epoxide-GSH Metabolite pubchem.compound:5486953
Aflatoxin B1 8,9-dihydrodiol Metabolite chebi:53106
Aflatoxin B1 dialdehyde Metabolite chebi:53107
aflatoxin B1 Metabolite hmdb:HMDB0006552
Aflatoxin B1 exo-8,9-epoxide Metabolite hmdb:HMDB0006558
Aflatoxin M1 Metabolite pubchem.compound:15558498
Aflatoxin Q1 Metabolite pubchem.compound:104757
AKR7A2 GeneProduct ensembl:ENSG00000053371
CYP1A2 GeneProduct ensembl:ENSG00000140505
AKR7A3 GeneProduct ensembl:ENSG00000162482
GSTT1 GeneProduct ensembl:ENSG00000277656
GSTM1 GeneProduct ensembl:ENSG00000134184
CYP2A13 GeneProduct ensembl:ENSG00000197838
EPHX1 GeneProduct ensembl:ENSG00000143819
CYP1A2 GeneProduct ensembl:ENSG00000140505
CYP1A2 GeneProduct ensembl:ENSG00000140505
CYP2A13 GeneProduct ensembl:ENSG00000197838
CYP3A4 GeneProduct ensembl:ENSG00000160868
CYP3A4 GeneProduct ensembl:ENSG00000160868


  1. Glutathione S-transferase-catalyzed conjugation of bioactivated aflatoxin B(1) in human lung: differential cellular distribution and lack of significance of the GSTM1 genetic polymorphism. Stewart RK, Smith GB, Donnelly PJ, Reid KR, Petsikas D, Conlan AA, et al. Carcinogenesis. 1999 Oct;20(10):1971–7. PubMed Europe PMC Scholia
  2. Reduction of aflatoxin B1 dialdehyde by rat and human aldo-keto reductases. Guengerich FP, Cai H, McMahon M, Hayes JD, Sutter TR, Groopman JD, et al. Chem Res Toxicol. 2001 Jun;14(6):727–37. PubMed Europe PMC Scholia
  3. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Tiemersma EW, Omer RE, Bunschoten A, van’t Veer P, Kok FJ, Idris MO, et al. Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):785–91. PubMed Europe PMC Scholia
  4. Reaction of aflatoxin B(1) oxidation products with lysine. Guengerich FP, Arneson KO, Williams KM, Deng Z, Harris TM. Chem Res Toxicol. 2002 Jun;15(6):780–92. PubMed Europe PMC Scholia
  5. Translational strategies for cancer prevention in liver. Kensler TW, Qian GS, Chen JG, Groopman JD. Nat Rev Cancer. 2003 May;3(5):321–9. PubMed Europe PMC Scholia
  6. Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. He XY, Tang L, Wang SL, Cai QS, Wang JS, Hong JY. Int J Cancer. 2006 Jun 1;118(11):2665–71. PubMed Europe PMC Scholia
  7. Cytochrome P450s and other enzymes in drug metabolism and toxicity. Guengerich FP. AAPS J. 2006 Mar 10;8(1):E101-11. PubMed Europe PMC Scholia
  8. CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Zhu LR, Thomas PE, Lu G, Reuhl KR, Yang GY, Wang LD, et al. Drug Metab Dispos. 2006 Oct;34(10):1672–6. PubMed Europe PMC Scholia
  9. Aldo-keto reductases and bioactivation/detoxication. Jin Y, Penning TM. Annu Rev Pharmacol Toxicol. 2007;47:263–92. PubMed Europe PMC Scholia
  10. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Barski OA, Tipparaju SM, Bhatnagar A. Drug Metab Rev. 2008;40(4):553–624. PubMed Europe PMC Scholia